Crestwood Advisors Group LLC Sells 615 Shares of iShares Biotechnology ETF (NASDAQ:IBB)

Crestwood Advisors Group LLC trimmed its position in iShares Biotechnology ETF (NASDAQ:IBB) by 3.4% in the third quarter, HoldingsChannel reports. The firm owned 17,284 shares of the financial services provider’s stock after selling 615 shares during the quarter. Crestwood Advisors Group LLC’s holdings in iShares Biotechnology ETF were worth $2,516,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in IBB. Main Management ETF Advisors LLC grew its position in shares of iShares Biotechnology ETF by 2.6% during the 2nd quarter. Main Management ETF Advisors LLC now owns 578,835 shares of the financial services provider’s stock valued at $79,451,000 after acquiring an additional 14,535 shares during the period. Raymond James Financial Services Advisors Inc. grew its position in shares of iShares Biotechnology ETF by 24.6% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 217,047 shares of the financial services provider’s stock valued at $29,792,000 after acquiring an additional 42,822 shares during the period. Raymond James & Associates grew its position in shares of iShares Biotechnology ETF by 4.4% during the 2nd quarter. Raymond James & Associates now owns 189,766 shares of the financial services provider’s stock valued at $26,047,000 after acquiring an additional 7,931 shares during the period. Osaic Holdings Inc. grew its position in shares of iShares Biotechnology ETF by 9.4% during the 1st quarter. Osaic Holdings Inc. now owns 160,173 shares of the financial services provider’s stock valued at $21,985,000 after acquiring an additional 13,777 shares during the period. Finally, Albion Financial Group UT grew its position in shares of iShares Biotechnology ETF by 0.3% during the 3rd quarter. Albion Financial Group UT now owns 129,980 shares of the financial services provider’s stock valued at $18,925,000 after acquiring an additional 356 shares during the period. 62.45% of the stock is owned by institutional investors.

iShares Biotechnology ETF Price Performance

iShares Biotechnology ETF stock opened at $145.06 on Wednesday. iShares Biotechnology ETF has a twelve month low of $113.56 and a twelve month high of $150.57. The firm has a 50 day moving average price of $144.86 and a 200-day moving average price of $140.84.

iShares Biotechnology ETF Announces Dividend

The firm also recently disclosed a dividend, which was paid on Monday, September 30th. Investors of record on Wednesday, September 25th were issued a $0.2005 dividend. The ex-dividend date of this dividend was Wednesday, September 25th.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.